Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
The purpose of this study is to test the safety and efficacy of study drug LY3526318 in participants with diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have daily pain for at least 12 weeks
Participants must have a body mass index of <40 kilograms per meter squared (kg/m²)
Participants must be willing to maintain any non-drug pain relieving therapies (for example, physical therapy) and not start any new non drug pain-relieving therapies during the study
Participants must be willing to stop all pain medications for diabetic nerve pain, except for rescue medication allowed in the study
Participants must have type 1 or type 2 diabetes and stable glycemic control
Participants Must Not:
Participants must not have surgery planned during the study for any reason
Participants must not have had cancer within 2 years, except for certain types of skin cancer (cutaneous basal cell or squamous cell carcinoma) surgically removed
Participants must not have an intolerance to acetaminophen or paracetamol
Participants must not have a history of alcohol or drug disorder within 2 years
Participants must not have a current drug-induced neuropathy, for example, due to some types of chemotherapy, or other types of peripheral neuropathy
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo